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Abstract The association of sleep apnea hypopnea syndrome (SAHS) with high leg activity in the same patient is a
dilemma for thephysician, as clonazepam, used totreatperiodic legmovement syndrome (PLMS) can aggravate apneas,
while nasal continuous positive airway pressure (nCPAP) can exacerbate PLMS.The present study aimed to compare
nCPAP alone (n), nCPAP combined with clonazepam (n+c) and clonazepam alone (c) in patients with mild to moderate
SAHSassociatedwithhighlegactivity.Fourteenpatientswith anapneahypopnea index (AHI) between10 and 50 h1and
alegmovementindexwithregardtotimeinbed [LMI (TIB)]415 h1onbaselinepolysomnography (b)wererecordedon
three consecutivenightswithn, n+c andc, respectively.Legmovementswere detected, usingactigraphy, andwere sub-
sequentlycategorized into periodic, apnea- or hypopnea- related andnonperiodicmovements (defined as neither peri-
odic nor related to a respiratory event).The three treatmentswere successful in improving breathing [AHIb 26.1 (3.2) n
11.8 (2.4) n+c 5.0 (0.7) c14.9 (1.8) h1], legactivity [LMI (TIB) b 39.1 (4.8) n 22.5 (4.4) n+c 23.9 (3.9) c 22.6 (3.7) h1] and sleep
fragmentation [stage shift index b 37.3 (2.6) n 28.6 (1.6) n+c 25.6 (1.8) c 26.6 (1.6) h1]. All types of movements were
reduced, the effect being significant for respiratory events related and nonperiodic movements.Combination therapy
was more effective than nCPAP alone in reducing the AHI and in improving sleep efficiency.We conclude that in
patients with mild to moderate SASH associated with high leg activity, nCPAP improves nocturnal breathing
and clonazepam reduces leg activity. More unexpectedly, nCPAP is beneficial on leg activity and clonazepam on
breathing, probably through a decrease in sleep fragmentation. The best results are obtained with combination
therapy.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1333, available online athttp://www.idealibrary.comon
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clonazepam; sleep fragmentation.INTRODUCTION
Dyssomnia, morning fatigue and daytime sleepiness are
frequent symptoms in patients with sleep apnea hypop-
nea syndrome (SAHS).Nasal continuous positive airway
pressure (nCPAP), when applied at e¡ective level,
abolishes apneas and hypopneas, increases oxyhemoglo-
bin saturation, stabilizes sleep and usually improves
symptoms. Some SAHSpatients, however, remain symp-
tomatic on domiciliary nCPAP, despite a good compli-
ance and a dramatic decrease in their apnea hypopnea
index (AHI). One possible explanation for failure ofReceived 26 October 2001, accepted in revised form 5 March 2002.
Correspondence should be addressed to:Dr A.Noseda,Chest
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Belgium.Fax: 32 2 555.64.90; E-mail: andre.noseda@chu-brugmann.benCPAP is (1) the association with a periodic leg move-
ment syndrome (PLMS). Periodic legmovements are re-
petitive and highly stereotyped movements, typically
involving dorsi£exion of the big toe and ankle and some-
times also £exion of the knee and hip. They last 0.5^5 s
and the intermovement interval ranges 5^90 s.They re-
present a potential cause for sleep disruption (2).The as-
sociation of SAHS and PLMS seems a rather common
¢nding, particularly in senior patients complainingofdys-
somnia and/or sleepiness (3,4). The treatment of these
two conditions in a same patient is di⁄cult. Indeed, clo-
nazepam is proposed as a ¢rst-line agent to treat PLMS
(2,5) but is considered as contraindicated by sleep apnea
(6).Conversely, nCPAP treatment for SAHS has been re-
ported to exacerbate a pre-existing PLMS (7). Further-
more, the justi¢cation for studying only periodic
694 RESPIRATORYMEDICINEmovements may be questioned. Nonperiodic leg
movements have been reported in patients with SAHS
(8,9) and in patients with other sleep disorders (9) but
their pathological relevance has not yet been agreed
upon.
In our Sleep Unit, recording and counting of all leg
movements either periodic or not, is a systematic policy.
The present study was designed to prospectively evalu-
ate the optimal strategy in patients showing the associa-
tion of SAHSwith high legmotor activity, in a setting of
acute trial in the Sleep Unit. In each patient, three
treatmentmodalities, namelynCPAP alone, nCPAP com-
bined with clonazepam and clonazepam alone were,
respectively, assessed on three consecutive nights.
Subsequently, home treatment was prescribed by
the physician on basis of the results of these three night-
trials and the patients were followed up at the Chest
Clinic.
METHODS
Study design
A group of subjects having SAHS combined with a high
leg movement index as assessed from a baseline poly-
somnography were recorded in the Sleep Unit for three
consecutive nights. All subjects gave informed consent
after full explanation of the study protocol.On the ¢rst
night, nCPAPwas started at an initial pressure of 4mbar,
and then was gradually increased until most apneas
and hypopneas were abolished and snoring was elimi-
nated. On the second night, subjects were given 1mg
clonazepam 30min before bedtime and slept on nCPAP,
at an e¡ective pressure as assessed from the ¢rst night.
On the third night, they were given 1mg clonazepam
30min before bedtime but sleptwithout nCPAP.The de-
cision for home treatment was left to the discretion of
the physician. All patients were followedup at the Chest
Clinic.
Subjects
Fourteen outpatients were recruited to participate in
this study. All hadpresentedwith one ormore of the fol-
lowing complaints: snoring, restless sleep, morning fati-
gue, daytime sleepiness.
All of them showed on baseline polysomnography a
mild-to-moderate SAHS, de¢ned as an AHI between 10
and 50h1, combined with a leg movement index (LMI)
4 15h1.Patientswith severe SAHS (AHI450h1),with
medical conditions (diabetes, renal disease) or on medi-
cations (tricyclic antidepressants) known to exacerbate
PLMS, were not admitted.Polysomnography
All night polysomnography was performed using stan-
dard sleeprecording leads (electro-oculogram,EEG, chin
electromyogram), ECG, nasobuccal thermistor, thoracic
and abdominal belts, transcutaneous oxymetry with ear
probe and leg actigraphy. Sleep staging was performed
according to the criteria of Rechtscha¡en and Kales on
20 s epochs (10).Time in bed (TIB) was de¢ned as the to-
tal time of recording, sleep period time (SPT) as the time
from the onset of sleep to the last awakening in the
morning, and total sleep time (TST) as SPT minus any
time the subject was awake after falling asleep. Sleep ef-
¢ciency (SE) was the ratio of TST toTIB, expressed as a
percentage, and stage shift index (SSI) was the sum of all
stage shifts divided by SPT, expressed as a number per
hour. Rapid eye movement sleep (REMS) proportion
and slow wave sleep (SWS) proportion were reported
as percentages of SPT. Apnea was de¢ned as a cessation
of £ow at the nose andmouth for at least10 s.Hypopnea
was scored as a decrease for at least10 s of the amplitude
of the rib cage and abdomen motion signals to less than
50% of the level prevailing before the event, coupled
with a fall in oxyhemoglobin saturation (SaO2) of 3% or
more. The AHI was calculated as the sum of all apneas
andhypopneas dividedbyTSTand expressed as a number
of events per hour. The maximal duration of either ap-
neas or hypopneas (Dmax) was also retained for analysis.
Apneaswere considered as obstructive if thoracicmove-
ments persistedduring the cessation of £ow, and the ob-
structive apnea index (OAI) was calculated as the sum of
all obstructive apneas divided byTST, and expressed as a
number of events per hour.
The motor activity of both legs was recorded, using
actigraphy, and the movements were scored visually.
The number of leg movements having occurred during
periods of e¡ective sleep, divided byTST, yielded the leg
movement index with regard to total sleep time [LMI
(TST)] and the total number of leg movements divided
by TIB yielded the leg movement index with regard to
time in bed [LMI (TIB)]. Subsequently, a categorization
of legmovementswasmade, using a speci¢cally designed
software. Movements were classi¢ed into periodic
movements, according to Coleman’s criteria (11), move-
ments related to an apnea or a hypopnea, de¢ned as oc-
curring during post-apneic, or post-hypopneic,
resumption of ventilation, andmovements being neither
periodic nor related to a respiratory event. All record-
ings were visually checked by an experienced lecturer
(MK), in order to detect and to correct any erroneous
categorization made by the software.Dividing the num-
ber of each type of movements by theTIB yielded, re-
spectively, a periodic leg movement index [PLMI (TIB)],
an apnea- or hypopnea-related leg movement index
[AHLMI (TIB)] and a nonperiodic leg movement index
[NPLMI (TIB)].
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An analysis of variance with repeated measures was
used.The data from the four recording nights (baseline;
nCPAP; nCPAP plus clonazepam; clonazepam) were ¢rst
globally analyzed to search for a possible treatment ef-
fect. If such an e¡ect was identi¢ed, pairwise compari-
sons were performed between the di¡erent nights
(baseline vs nCPAP; baseline vs nCPAP plus clonazepam;
baseline vs clonazepam; nCPAP vs nCPAP plus clonaze-
pam; nCPAP vs clonazepam; nCPAP plus clonazepam vs
clonazepam). As usually, statistical signi¢cance was con-
sidered to be achievedwhen Pr0.05.
RESULTS
Patients
Fourteenpatientswererecruited. Allbutoneweremen.
Their anthropometric featureswere [mean (SD)]: age 54
(12) years, height175 (7) cm,weight 91 (18) kg, bodymass
index 29.6 (5.3) kgm2. Baseline polysomnography
showed (Table 1) SAHS of moderate severity, mean leg
movement indices around 35h1 and marked sleep frag-
mentation. Where breathing abnormalities are con-
cerned, the preponderance of hypopneas was a
remarkable ¢nding, as they representedmore than 50%
of breathing abnormalities in all patients (70.5% on aver-
age). As the motor activity of the contralateral leg
yielded no additional information, LMI (TST), LMI (TIB),TABLE 1. Polysomnographic variablesin14 patientswith sleepap
index, at baseline and during the three treatmentnights
Baseline nCPAP
AHI (h1) 26.1 (3.2) 11.8 (2.4)**
Dmax (s) 52.7 (4.9) 36.9 (3.4)*
OAI (h1) 4.0 (1.0) 0.3 (0.1)**
LMI (TST) (h1) 37.9 (5.3) 20.6 (5.4)*
LMI (TIB) (h1) 39.1 (4.8) 22.5 (4.4)**
PLMI (TIB) (h1) 21.7 (4.6) 12.3 (3.1)
AHLMI (TIB) (h1) 7.3 (1.7) 2.4 (0.6)**
NPLMI (TIB) (h1) 10.1 (1.0) 7.8 (1.2)
SE (%) 79.1 (2.2) 73.8 (2.7)
REMS (%) 14.5 (1.8) 11.9 (1.9)
SWS (%) 3.4 (0.9) 2.5 (0.9)
SSI ((h1) 37.3 (2.6) 28.6 (1.6)**
AHI = apnea hypopnea index;Dmax = maximal duration of ap
LMI (TIB) = legmovement index (with regard to total sleep time)
(TIB) = periodic legmovement index, apnea orhypopnea related
regardtotimeinbed);SE = sleep e⁄ciency;REMS = proportion
sleep;SSI = stage shift index.Data in the table aremean (SEM) va
*Po0.05; **Po0.01; ***Po0.001for pairwise comparison of eacPLMI (TIB), AHLMI (TIB) and NPLMI (TIB) were re-
ported only for the left leg.
Therapeutic trial
The evolution of each variable during the three night-
acute treatment trial is shown in Figs 1^3. The global
treatment e¡ect of the three night protocol reached sig-
ni¢cance, except for REMS (P = 0.140) and for PLMI (TIB)
(P =0.114). In comparisonwithbaselinepolysomnography
(Table 1), nCPAP alone improved all the respiratory and
some of the leg motor variables, as well as the SSI. The
bene¢cial e¡ect of nCPAP on periodic movements (P =
0.084) and on nonperiodic movements (P = 0.077) drew
near signi¢cance.Using the same comparisonwith base-
line, nCPAP plus clonazepam was e¡ective in improving
all the respiratory and the leg movement variables (ex-
cept for periodic movements), the SE and the SSI (Table
1). The pairwise comparison clonazepam alone vs base-
line showed a bene¢cial e¡ect on the AHI, the legmotor
variables (except for periodic movements), the SE and
the SSI and a deleterious e¡ect on the SWS (Table1).
Between-treatment comparisons showed (Table 2)
that combination therapy wasmore e¡ective than either
nCPAP alone or clonazepam alone in reducing the AHI.
Where obstructive apneas are concerned, as shown in
Table 2, either combination therapy or nCPAP alonewas
more e¡ective than clonazepam alone. A similar di¡er-
ence in e¡ectiveness was observed in reducing maximal
apnea or hypopnea duration with, however, only theneahypopnea syndrome associatedwith ahighlegmovement
nCPAP + clonazepam Clonazepam
5.0 (0.7)*** 14.9 (1.8)**
32.9 (2.9)** 49.1 (5.8)
0.1 (0.1)** 3.3 (1.0)
20.5 (4.3)* 18.9 (3.7)*
23.9 (3.9)* 22.6 (3.7)*
16.8 (3.4) 12.9 (3.2)
1.5 (0.6)** 2.6 (0.7)*
5.6 (1.0)** 7.1 (0.8)**
86.2 (1.4)* 86.1 (1.8)*
15.6 (1.7) 15.9 (1.5)
3.0 (1.1) 1.2 (0.5)**
25.6 (1.8)*** 26.6 (1.6)**
nea or hypopnea;OAI = obstructive apnea index;LMI (TST),
(with regard to time in bed); PLMI (TIB), AHLMI (TIB),NPLMI
legmovement index, nonperiodic legmovement index (with
ofrapideyemovement sleep;SWS= proportionof slowwave
lues.
htreatmentnightwith baseline.
FIG. 1. Meanvalues of respiratory variables in14 patientswith
sleep apnea hypopnea syndrome associatedwith high legmotor
activity.Baseline, nCPAPalone, nCPAPplus clonazepamandclo-
nazepam alone are represented, respectively, as black, heavy
gray, lightgrayandwhite columns.AHI = apneahypopnea index,
Dmax = maximal duration of apnea orhypopnea,OAI =obstruc-
tive apnea index.
FIG. 2. Mean values of leg motor activity variables in 14 pa-
tientswith sleepapneahypopnea syndromeassociatedwithhigh
leg motor activity.Otherwise same legend as Fig.1. LMI (TST),
LMI (TIB) = legmovement index (withregard tototal sleeptime)
(with regard to time in bed), PLMI (TIB), AHLMI (TIB), NPLMI
(TIB) = periodic leg movement index, apnea or hypopnea re-
lated leg movement index, nonperiodic leg movement index
(withregard to time in bed).
FIG. 3. Mean values of sleep variables in14 patients with sleep
apnea hypopnea syndrome associatedwithhigh legmotoractiv-
ity.Otherwise samelegendas Fig.1.SE = sleep e⁄ciency,REMS=
proportion of rapid eyemovement sleep, SWS = proportion of
slowwave sleep,SSI = stage shift index.
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pam alone reaching signi¢cance. Where leg activity is
concerned, combination therapy was more e¡ective
than clonazepam alone in reducing movements related
to respiratory events.Finally, either combination therapy
or clonazepam alone was more e¡ective than nCPAP
alone in increasing SE (Table 2).
Clinicalmanagement
Ten outof14 patientswereprescribed combined therapy
at home, while four patients were given nCPAP alone.
Out of these10 patients on combined therapy, seven didwell (median follow-up of 24 months) with, however, a
need to reduce the dose of clonazepam to 0.5mg in two
subjects.Two subjects did not tolerate nCPAP, were sub-
sequently treated by clonazepam alone, and ¢nally did
well.One patient did not tolerate clonazepam and ¢nally
did well on nCPAP alone. Out of the four patients on
nCPAP alone, two did well while two did not tolerate
nCPAP.
DISCUSSION
The association of SAHS with high leg motor activity in
the same patient represents both a diagnostic problem
and a therapeutic dilemma for the physician. Firstly, the
real signi¢cance of high leg activity is not clear. Usually,
periodic movements are considered to be a potential
cause for sleep disruption (2) while the signi¢cance of
legmovements that are not periodic is largely unknown.
However, the traditionally used classi¢cation forperiodi-
city accepts intermovement intervals between 5 and
90 s; as a consequence, the so-called periodic move-
ments include, in fact, a large heterogeneity of move-
ment patterns. In the present study, we detected leg
movements using actigraphyFamethodwhich has been
validated (12)Fand we decided to score all movements,
whatever periodic or not. Secondly, where therapy is
concerned, clonazepamFone of the most used agents
to treat PLMS (2)Fbelongs to the class of thebenzodia-
zepines, which are usually considered to be contraindi-
cated in the presence of SAHS. This notion is based
both on experimental evidence as diazepam depresses
the motor activity of upper airway muscles in the de-
cerebrate cat (13), and as triazolam increases the arousal
threshold to airway occlusion in patients with severe
TABLE 2. Analysis of variancewith pairwise comparison betweentreatment nights, in14 patientswith sleep apnea hypopnea
syndrome associatedwith a high legmovement index
nCPAP +
clonazepam/nCPAP
Clonazepam/nCPAP Clonazepam/nCPAP
+ clonazepam
AHI 0.005 0.322 o0.001
Dmax 0.302 0.083 0.013
OAI 0.342 0.008 0.006
LMI (TST) 0.989 0.767 0.681
LMI (TIB) 0.722 0.987 0.683
AHLMI (TIB) 0.161 0.739 0.040
NPLMI (TIB) 0.104 0.528 0.139
SE o0.001 0.002 0.967
SWS 0.593 0.045 0.058
SSI 0.090 0.193 0.625
Data inthe table are P values.SeeTable1formeaning of abbreviations.
SLEEPAPNEAS,HYPOPNEASANDLEGMOVEMENTS 697SAHS (14) and on clinical experience showing that £ura-
zepamcan induce apneas in normal subjects (15), particu-
larly in the elderly (16). Conversely, nCPAP F largely
considered as the treatment of choice for SAHSF can
exacerbate PLMS (7). It has been hypothesized that, in
SAHS patients, the PLMSmay be disguised until apnea is
treated (1), but the inadvertent application of nCPAP in a
patientwithout sleep apnea has been reported to induce
PLMS, suggesting a role of nCPAP itself (17). In clinical
practice, it is often considered a priority to treat SAHS,
as it is a condition associated with signi¢cant mortality
(18) while excessive leg motor activity is considered as
benign and is therefore neglected when it is associated
with SAHS.However, some SAHS patients still complain
of dyssomnia, morning fatigure and daytime sleepiness
when adequately treated by nCPAP at home. In our ex-
perience as in that of others (1), the coexistence of PLMS
is a common ¢nding in these subjects and appropriate
treatment with clonazepam may be e¡ective in improv-
ing symptoms in at least some of these subjects.
The present study aimed at comparing patients with
combined SAHS and high leg motor activity nCPAP
alone, nCPAP plus clonazepam and clonazepam alone in
an acute trial in the Sleep Unit over three consecutive
nights. This study has several limitations. Firstly, the
three modes of treatment were not randomized. We
considered that itwas inappropriate to administer clona-
zepam, either alone or combined with nCPAP, on the
¢rst night and to withdraw it on the second night, as
acute withdrawal of a benzodiazepine agent may induce
or exacerbate dyssomnia.That is why a ¢xed successive
design was used, with clonazepam given on the second
and third nights. Secondly, it may be argued that, as the
¢rst night consisted in a nCPAP titration procedure, the
subjects slept during the initial part of this ¢rst night at
suboptimal pressure, which could bias the comparisonbetween the ¢rst (nCPAP alone) and the second night
(nCPAPplus clonazepam) in favor of the latter one.How-
ever, a large between-subject variability in the time
needed to reach the e¡ective pressure prevented us
from taking into account solely that part of the ¢rst
night where the optimal pressure had been reached.
Thirdly, it may be questioned whether F during the
third nightF there was some residual e¡ect of nCPAP,
applied during the two preceding nights. The bene¢cial
e¡ect of nCPAP has indeed been shown to persist for
some time when the mask is o¡, partly because of a de-
crease in mucosal edema in the upper airway (19). How-
ever, this decrease in edema is obtained only after
several nights on nCPAP and is very unlikely to be in-
volved in an acute trial setting.
In comparisonwithbaselinepolysomnography, nCPAP
improved nocturnal breathing and clonazepam de-
creased leg movements, as expected. More unexpect-
edly, nCPAP was e¡ective in reducing legmotor activity
and clonazepam signi¢cantly reduced the AHI.The cate-
gorization of leg movements into periodic movements,
movements related to respiratory events and nonperio-
dic movements allowed us to re¢ne the analysis of treat-
ment e¡ects.We found that the movements related to
apneas or hypopneas decreased with the three treat-
ments and that both clonazepam and combination ther-
apy reduced the nonperiodic movements, while the
periodic movements were poorly in£uenced by the
treatment protocol (except for a bene¢cial trend with
nCPAP alone). Again, the bene¢cial e¡ect of nCPAP on
respiratory events relatedmovements was an expected
¢nding, while that of clonazepam on the same type of
movementswasmuchmoreunexpected. Anunifying ex-
planation for the unexpected bene¢ts obtained with
nCPAP (on leg motor activity) and with clonazepam (on
breathing) is a bene¢cial e¡ect mediated by stabilizing
698 RESPIRATORYMEDICINEsleep. Indeed, it iswellknown that apneas andhypopneas
disrupt sleep, but conversely sleep fragmentation itself
can be the primary element in repetitive abnormal
breathing pattern (20). Similarly, legmovements can dis-
rupt sleep, but conversely a poor sleep architecture,
with REMS and SWS de¢ciency, can favor legmovements
(21). In the particular population studied, here character-
ized by apneas andFpredominantlyFhypopneas, asso-
ciated with high leg motor activity, an improvement in
sleep continuity may, whatever be its cause, have re-
sulted in less respiratory events and less motor events.
The observation that clonazepam alone reduced the
overall number of respiratory events, but not the ob-
structive apneas, supports this interpretation. Even
more supportive for this interpretation is the observa-
tion that periodic movements showed a trend to de-
crease with nCPAP and that apnea- or hypopnea-
relatedmovements decreasedwith clonazepam.
The results of this study, performed in a clinical set-
ting, suggest that it may be useful to add clonazepam to
nCPAP in a patient having an excessive legmotor activity
associated with moderate SAHS.The expected bene¢ts
fromcombined therapy are an additional improvement in
the AHI and an increase in sleep e⁄ciency. However,
with the acute trial design used in the present study, the
¢rst night with nCPAP often does not demonstrate, as
discussed hereinabove, the full e¡ect of this treatment,
and the better results obtained with nCPAP plus clona-
zepam could be due, at least partly, to a second night ef-
fect rather than to the addition of clonazepam.Whether
the improvement in sleep on combined therapy, com-
pared with nCPAP alone, is sustained during long-term
home therapy and whether this improvement adds to
the quality of vigilance of the patients remains to be de-
monstrated. The usual statement that benzodiazepine
agents are contraindicated in any patient with SAHS (6)
is possibly an overstatement. Some recent studies have
indeed shown that nitrazepam e.g. does not worsen
sleep apnea in patients with-mild-to-moderate SAHS
(22).The present study shows that a1mg dose of clona-
zepam, associated with nCPAP, is safe and bene¢cial in
patients with moderate SAHS and high leg motor activ-
ity.Our results also suggest that a1mg dose of clonaze-
pam alone is deleterious for the SWS but is safe where
breathing is concerned, at least in the very short term.
These results should not be extrapolated to patients
with severe SAHS. The present study should be consid-
ered, in view of its methodological limitations, as a pre-
liminary investigation. In further research, a three night
acute trial design could be improved by telling the sub-
jects that combined therapy is given on all nights and by
adding an oral placebo (¢rst night) and a sham nCPAP
(third night). Alternately, subjects on maintenance ther-
apy with nCPAP for someweeks could be studied at the
Sleep Unit with the addition of either an oral placebo or
clonazepam.Acknowledgements
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